The leukocyte specific beta2 integrins are central to the biological function of these cells. Beta2 integrins mediate the divalent metal ion dependent adhesion of leukocytes including homing, firm adhesion, migration, respiratory burst and clearance of pathogens through phagocytosis and cell-mediated killing, beta2 integrins also contribute to injury in many non-infectious diseases, such as renal failure, allograft rejection, heart attacks, strokes and autoimmune diabetic complications, where the receptors are pathologically activated. Therefore, beta2 integrins are important therapeutic targets in inflammation, autoimmunity, and transplantation. Integrins use bi-directional signaling to regulate cellular functions. Inside-out signals activate integrins by inducing conformational changes in their extracellular ligand-binding domains. Structural basis for integrin activation is poorly understood and is a focus of intense current research. Recently described high-resolution alphaVbeta3 integrin crystal structures highlight distinctive features of the integrin dimers and provide new insights into the nature of their activation.
Our aim i s to develop and test specific, structure-based hypotheses for integrin activation, with a focus on beta2 integrin CD11b/CD18, by using alphaVbeta3 structure as the model for the CD11b/CD18 integrin. We will generate mutations in integrin subunits and study their effect on integrin activation and biological function using cell-based and biochemical assays.
In aim 1, we will evaluate the basis of metal ion coordination at alpha-Genu, and determine the role of flexion in allosteric integrin activation. Alpha-genu is the knee structure in the alpha-subunit that lies between the thigh and the calf-1 domains. The structure serves as a highly flexible hinge, and is the site of the bend in the crystal structure that has a divalent metal ion associated with it.
In aim 2, we will examine the deadbolt hypothesis and study the role of betaTD in inside-out activation of integrins. Beta tail domain (betaTD) is a novel domain that was found in beta-subunit in the integrin crystal structure. Comparison of unliganded and liganded integrin structures shows that this domain may regulate integrin activation by binding with the betaA domain and thereby acting as a deadbolt to keep integrins in an inactive form.
In aim 3, we will determine the function of a extracellular juxta-membrane residue in integrin homo-oligomerization and clustering. Sequence alignment between various integrins shows that there are a number of conserved residues between the betaTD and the transmembrane region. This residue may play a part in integrin activation or clustering. Given the importance of beta2 integrins in every aspect of leukocyte function, these studies will have a profound impact on cell biology and will facilitate design of novel therapeutics to treat the many diseases resulting from pathologic modulation of integrins. The insights gained from these studies are also likely to extend to other integrins.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Scientist Development Award - Research & Training (K01)
Project #
1K01DK068253-01
Application #
6814512
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Program Officer
Rankin, Tracy L
Project Start
2004-08-01
Project End
2009-06-30
Budget Start
2004-08-01
Budget End
2005-06-30
Support Year
1
Fiscal Year
2004
Total Cost
$129,870
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Greka, Anna; Weins, Astrid; Mundel, Peter (2014) Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 370:1263-6
Yu, Chih-Chuan; Fornoni, Alessia; Weins, Astrid et al. (2013) Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 369:2416-23
Adair, Brian D; Xiong, Jian-Ping; Alonso, José Luis et al. (2013) EM structure of the ectodomain of integrin CD11b/CD18 and localization of its ligand-binding site relative to the plasma membrane. PLoS One 8:e57951
Faridi, Mohd Hafeez; Maiguel, Dony; Brown, Brock T et al. (2010) High-throughput screening based identification of small molecule antagonists of integrin CD11b/CD18 ligand binding. Biochem Biophys Res Commun 394:194-9
Reiser, Jochen; Gupta, Vineet; Kistler, Andreas D (2010) Toward the development of podocyte-specific drugs. Kidney Int 77:662-8
Qureshi, Amir H; Chaoji, Vineet; Maiguel, Dony et al. (2009) Proteomic and phospho-proteomic profile of human platelets in basal, resting state: insights into integrin signaling. PLoS One 4:e7627
Banerjee, Abhisek; Sergienko, Eduard; Vasile, Stefan et al. (2009) Triple hybrids of steroids, spiroketals, and oligopeptides as new biomolecular chimeras. Org Lett 11:65-8
Faridi, Mohd Hafeez; Maiguel, Dony; Barth, Constantinos J et al. (2009) Identification of novel agonists of the integrin CD11b/CD18. Bioorg Med Chem Lett 19:6902-6
Wei, Changli; Moller, Clemens C; Altintas, Mehmet M et al. (2008) Modification of kidney barrier function by the urokinase receptor. Nat Med 14:55-63
Gupta, Vineet; Alonso, Jose Luis; Sugimori, Takashi et al. (2008) Role of the beta-subunit arginine/lysine finger in integrin heterodimer formation and function. J Immunol 180:1713-8

Showing the most recent 10 out of 12 publications